

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I and II

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I or II.